Ivermectin treatment of hyperreactive onchodermatitis (sowda) in Liberia.
Seventeen male and 39 female Liberian patients, one third of them children, were diagnosed as having hyperreactive onchodermatitis (sowda). They presented with itching (98%), asymmetric (98%), chronic onchodermatitis (median 5 years), and swelling of femoral lymph nodes (89%). The geometric means of the microfilaria (mf) densities were 1.0 mf/mg in children and 0.7 mf/mg in adults. These patients not only suffered from their skin lesions, and severe itching resulting in disturbance of sleep but also from social stigmata. They urgently needed treatment. Ivermectin was administered as a single oral dose of 150 micrograms/kg body weight. The following adverse effects were observed in 30 patients within the first 72 hours after ivermectin treatment: increase of pruritus (93%), aggravation of dermatitis (73%), fever (25%), headache (20%), myalgia (20%), painful swelling of lymph nodes (13%) and severe swelling of arm or leg (10%). Symptomatic therapy was sufficient. No dangerous or life-threatening side effects were observed. At follow-up examinations 1-2 months after ivermectin treatment, the prevalence of mf carriers had decreased from 100% to 19%. Seventeen out of 18 patients felt their dermatitis had improved. Evaluation of the dermatitis by a physician using a score from 0 (no dermatitis) to 9 (severe dermatitis) revealed a reduction of the score from 4.3 before treatment to 0.7 (84%) after ivermectin. In contrary, at the follow-up examination of 16 patients 6-12 months after ivermectin some recrudescences were observed. In this group the prevalence of mf carriers was 47%, 13 out of the 16 patients felt their skin lesions had improved and the score had decreased from 2.2 to 0.5 (77%). Consequently, it is recommended to administer ivermectin to patients with hyperreactive onchodermatitis every 3-4 months.
Darge
K
K
Department of Helminthology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Büttner
D W
DW
D000328:Adult; D000818:Animals; D000977:Antiparasitic Agents; D002648:Child; D004804:Eosinophils / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007559:Ivermectin / Q000009:adverse effects / Q000627:therapeutic use*; D007988:Liberia; D008297:Male; D008842:Microfilariae / Q000187:drug effects; D017181:Onchocerca volvulus / Q000187:drug effects / Q000302:isolation & purification*; D009855:Onchocerciasis / Q000188:drug therapy* / Q000473:pathology; D012876:Skin Diseases, Parasitic / Q000473:pathology
D000977:Antiparasitic Agents; D007559:Ivermectin